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Summary
 
Leukocyte infiltration and necrosis are two biological phenomena associated with the develop-
ment of neovascularization during the malignant progression of human astrocytoma. Here, we
demonstrate expression of interleukin (IL)-8, a cytokine with chemotactic and angiogenic
properties, and of IL-8–binding receptors in astrocytoma. IL-8 expression is first observed in
low grade astrocytoma in perivascular tumor areas expressing inflammatory cytokines. In glio-
blastoma, it further localizes to oxygen-deprived cells surrounding necrosis. Hypoxic/anoxic
insults on glioblastoma cells in vitro using anaerobic chamber systems or within spheroids de-
veloping central necrosis induced an increase in IL-8 messenger RNA (mRNA) and protein
expression. mRNA for IL-8–binding chemokine receptors CXCR1, CXCR2, and the Duffy
antigen receptor for chemokines (DARC) were found in all astrocytoma grades by reverse
transcription/PCR analysis. In situ hybridization and immunohistochemistry localized DARC
expression on normal brain and tumor microvascular cells and CXCR1 and CXCR2 expres-
sion to infiltrating leukocytes. These results support a model where IL-8 expression is initiated
early in astrocytoma development through induction by inflammatory stimuli and later in tu-
mor progression increases due to reduced microenvironmental oxygen pressure. Augmented
IL-8 would directly and/or indirectly promote angiogenesis by binding to DARC and by in-
ducing leukocyte infiltration and activation by binding to CXCR1 and CXCR2.
 
A
 
strocytomas are the most common and lethal human
primary brain tumors and can be subdivided into low
grade astrocytoma (WHO grade II), anaplastic astrocytoma
(grade III), and glioblastoma (grade IV) according to cellu-
larity, cellular pleomorphism, degree of neovascularization,
and the presence of necrosis (1). Glioblastoma can occur de
novo or as the recurrence of a grade II or III astrocytoma.
Little is known about the molecular mediators inducing the
biological changes occurring during this progression. Here
we address two interesting biological features of these tu-
mors: development of tumor-induced neovascularization
and the use of this vascular network by lymphoid/myeloid
cells for tumor infiltration.
As for other tumor types, the progression of astrocytoma
is dependent on the development of new blood supply (2,
3). New blood vessels appear in low grade astrocytoma;
these vessels are anatomically indistinguishable from those
found in the surrounding normal brain. In the malignant
phase of the disease, vessel density increases and the
neovessels acquire an abnormal architecture, becoming ex-
tensively convoluted with the formation of vascular glom-
eruli, showing lumen occlusion, and displaying hyperplasia
of the smooth muscle/pericyte and endothelial cell layers
(1, 3). Maximal vessel density is reached in glioblastoma
which is among the most vascularized tumors (4). Paradox-
ically, this increase in vessels is accompanied by the devel-
opment of necrosis, the pathognomonic criterion that dis-
tinguishes glioblastoma from anaplastic astrocytoma (1, 3).
The precise mechanism(s) at the origin of this tissue death
are unresolved, but at least two factors are believed to con-
tribute to its genesis. One is the outgrowth of blood supply
by a rapidly growing tumor leading to tissue hypoxia/an-
oxia. The second is thrombotic occlusion of vessels, con-
ducive to tissue ischemia (1).
Parallel to vessel development, astrocytomas are often in-
filtrated with numerous lymphoid/myeloid cells extravasat-
ing from newly formed tumor vessels. These are predomi-
nantly macrophages and CD8 T lymphocytes, but, B cells,
NK cells, and CD4 T cells are also present (5, 6). It is un-
clear whether these infiltrates participate in an antitumor
response or contribute indirectly to tumor expansion by se-
cretion of growth factors or cytokines. Clearly, they are in-
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efficient at eradicating tumor growth and do not appear to
relate to a favorable prognosis (7, 8). The precise mecha-
nism leading to infiltration in astrocytoma is unknown, but
it is likely to involve both adhesion molecules (9, 10) and
chemoattractants (11, 12).
IL-8 is a candidate molecule that may play a role in both
of these processes. Belonging to the subfamily of chemo-
kines blueprinted by a C-X-C amino acid cystein motif (see
review in reference 13), IL-8 is secreted by many different
cell types and is a chemoattractant for neutrophils, T lym-
phocytes, and basophils (14–19). Furthermore, recent work
has demonstrated that IL-8 is a mediator of angiogenesis.
IL-8 induces endothelial cell chemotactic and proliferative
activity (20–22) and mediates neovascularization in rat and
rabbit corneas in the absence of inflammation (23–24), as
well as in the rat mesenteric window assay (25). IL-8 is se-
creted by a variety of tumor cells (see review in reference
13), promotes growth of bronchogenic carcinoma (26) and
nonsmall cell lung cancer (22), and correlates with meta-
static potential of human melanoma cells in nude mice (27).
Three IL-8–binding receptors participate in the biologi-
cal responses mediated by this cytokine: C-X-C chemo-
kine receptor 1 (CXCR1/IL-8RA), C-X-C chemokine
receptor 2 (CXCR2/IL-8RB), and the Duffy antigen re-
ceptor for chemokines (DARC).
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 Although IL-8 is the
only chemokine known to bind to CXCR1, CXCR2 is
shared  with all C-X-C chemokines carrying the amino acid
motif E-L-R-C-X-C. DARC is a promiscuous receptor for
many C-X-C and C-C chemokines and serves as a site of
anchorage for infection by malaria parasite 
 
Plasmodium vivax
 
(28, 29).
We previously demonstrated that IL-8 is synthesized in
vivo during all stages of astrocytoma progression (12). Here
we examine which physiological mechanisms regulate IL-8
expression during the progression of human astrocytoma,
and elucidate whether this secretion mediates a biological
response in these tumors. We demonstrate that two mech-
anisms are likely to be involved in IL-8 secretion: early in-
duction by the presence of inflammatory signals such as IL-1
and TNF, and late induction by a change in the physiology
of the tumor, namely, a decrease in oxygen levels due to is-
chemia/hypoxia. Expression of IL-8 receptors CXCR1
and CXCR2 on a subset of infiltrating leukocytes and of
DARC on tumor microvasculature supports a role for IL-8
in leukocyte attraction, activation, and angiogenesis.
 
Materials and Methods
 
Cell Culture, Spheroid Formation, and Anoxic Treatments.
 
Human
glioblastoma cell lines U87MG (endogenous WTp53, tumori-
genic in immunocompromised mice), LN-229 (mutant p53, tu-
morigenic), LN-Z308 (p53-null, tumorigenic), and T98G (mutant
p53, nontumorigenic) were grown as previously described (30). To
 
induce anoxia, cells were incubated in an Oxoid gas generating
anaerobic system chamber (Unipath Ltd., Hamshire, UK) using
hydrogen, CO
 
2
 
, and a palladium catalyst to remove all traces of
oxygen (final anoxic conditions: 93% hydrogen, 7% CO
 
2
 
). Cells
(1.5 
 
3
 
 10
 
6
 
) were plated in tissue culture dishes 48 h before anoxic
induction. When the cultures reached 80% confluence, fresh cul-
ture medium (DMEM–5% FCS) was added and dishes were in-
cubated under normoxic or anoxic conditions for different times.
To allow spheroid formation, LN-229 cells were trypsinized and
2 
 
3
 
 10
 
4
 
 cells were seeded in 0.5% agar-coated wells (GIBCO
BRL, Gaithersburg, MD). Culture medium was changed every 2 d
and spheroids were incubated for 4–11 d until necrosis formation.
Spheroids were then embedded in Tissue-Tek OCT4583 (Miles
Inc., Elkhart, IN) and snap frozen in liquid nitrogen. Serial sec-
tions of 5-
 
m
 
m thickness were then processed for in situ hybridiza-
tion or immunohistochemistry.
 
Preparation of Conditioned Media for Measurement of IL-8 Produc-
tion by ELISA.
 
Culture supernatants of LN-229 were collected
after 4, 12, and 24 h under normoxic or hypoxic conditions, cen-
trifuged at 1,000 
 
g
 
, aliquoted, and stored at 
 
2
 
80
 
8
 
C until tested.
ELISA was done in duplicate using a commercially available assay
system according to the manufacturer’s instructions (R&D Sys.
Inc., Minneapolis, MN). The minimal detection limit was 3 pg/
ml of recombinant human IL-8 in the culture medium.
 
Tissue Specimens and Immunohistochemistry.
 
Astrocytoma spec-
imens and nontumoral brain tissue from pharmacoresistant epi-
lepsy patients were snap frozen in refrigerated isopentane and
stored at 
 
2
 
80
 
8
 
C. Cyostat tissue or spheroid sections were incu-
bated with optimal concentrations of the following primary anti-
bodies: anti–IL-8 hybridoma 46E5 (31), anti-CXCR1/IL-8RA
hybridoma 5A12-5, anti-CXCR2/IL-8RB hybridoma 6C6-1C
(18), anti-DARC polyclonal antibody 6615 and corresponding
rabbit preimmune serum (32), and purified monoclonal antibody
preparations against glial fibrillary acidic protein (GFAP) clone
6F2 (Dako, Copenhagen, Denmark), T cell marker CD3 clone
SK7 (Becton Dickinson, Basel, Switzerland), and isotype-matched
mouse immunoglobulins as negative controls (Dako). The sec-
tions were then incubated for 25 min with a biotinylated anti–
mouse IgG horse antibody (Vector Labs., Burlingame, CA), fol-
lowed by a 25-min incubation with peroxidase-labeled avidin.
The chromogens used were 3-amino-9-ethylcarbazole (Sigma
Chemical Co., St. Louis, MO) or 3,3
 
9
 
-diaminobenzidine (Fluka
Chemie AG, Buchs, Switzerland). Counterstaining was done with
hematoxylin for 30 s.
 
RNA Extraction and Reverse Transcriptase/PCR.
 
Total RNA
from resected human astrocytomas (5 grade II, 7 grade III, and 12
grade IV) and from four cell lines (LN-229, T98G, LN-Z308,
and U87MG) were extracted with TRIzol Reagent as described
by the manufacturer (GIBCO BRL). The reverse transcription
(RT)/PCR was done with 1 
 
m
 
g of total RNA as previously de-
scribed (11). The following primer pairs were used; annealing
temperatures, MgCl
 
2
 
 concentrations, and amplicon sizes are indi-
cated in brackets. For IL-8: 5
 
9
 
 primer (5
 
9
 
 ATG ACT TCC AAG
CTG GCC GTG 3
 
9
 
), and 3
 
9
 
 primer (5
 
9
 
 CTC TTC AAA AAC
TTC TCC CGA CTC TTA AGT ATT 3
 
9
 
) [65
 
8
 
C, 1.5 mM, 298
bp]; for CXCR1: primer A (5
 
9
 
 GAG GTT GTG TGT GGA
AGG TG 3
 
9
 
), and primer B (5
 
9
 
 AGG TTG ATG TTT TGG
CAG TG 3
 
9
 
) [64
 
8
 
C, 1 mM, 476 bp]; for CXCR2: primer A (5
 
9
 
GCT CTA GAG CTG GGC AAC AAT ACA GCA AACT 3
 
9
 
)
and primer B (5
 
9
 
 CCA TCG ATG GGC ACT TAG GCA GGA
GGT CTTA 3
 
9
 
) [60
 
8
 
C, 1.5 mM, 493 bp]. RT controls included
reactions without mouse Moloney leukemia virus (MMLV) re-
verse transcriptase and without RT product.
 
1
 
Abbreviations used in this paper:
 
 DARC, Duffy antigen receptor for
chemokines; GFAP, glial fibrillary acidic protein; mRNA, messenger RNA;
RT, reverse transcription; VEGF, vascular endothelial growth factor. 
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Northern Blot Analysis.
 
10 
 
m
 
g of RNA/sample were electro-
phoresed through a 1% agarose formaldehyde gel and blotted
onto a nitrocellulose membrane (Hybond N; Amersham, Ayles-
bury, UK) as previously described (11). The blots were hybrid-
ized with the following probes labeled by random primed DNA
labeling kit (Boehringer Mannheim, Indianapolis, IN): a 298-bp
PCR fragment of IL-8 cDNA (see above), a 500-bp EcoRI–
BamHI fragment of human vascular endothelial growth factor
(VEGF) cDNA (plasmid pBluescript KS-VEGF), a 1,100-bp PstI
fragment of 
 
b
 
 actin cDNA (plasmid pAL41), and a 280-bp EcoRI
fragment of the bovine 28S ribosomal DNA gene.
 
In Situ Hybridization.
 
In situ hybridization was performed as
previously described (11) using the following cRNA sense and
antisense probes labeled with 
 
35
 
S-UTP during in vitro transcrip-
tion reactions with T3 or T7 RNA polymerase: a 240-bp PstI–
EcoRI fragment of the IL-8 cDNA, a 477-bp EcoRI–XhoI
CXCR1 cDNA fragment (33), a 1,510-bp EcoRI–XhoI CXCR2
cDNA fragment (34), and, as a positive control, a BamHI–EcoRI
VEGF
 
165
 
 cDNA fragment.
 
Results
 
Previous work established that IL-8 is produced in patients
with all grades of astrocytoma progression. Interestingly,
immunohistochemistry showed predominant IL-8 localiza-
tion on tumor cells or macrophages in perivascular areas
with leukocytic infiltrates and on pseudopalisading cells
surrounding necrosis (12), a spatial pattern that is compati-
ble with a role in chemotaxis and/or angiogenesis. How-
ever, localization of cytokine secretion sites on this basis
may be misleading and be the result of cytokine sequestra-
tion rather than production. To unequivocally identify the
Figure 1. Detection of IL-8 mRNA in
glioblastoma sections by in situ hybridiza-
tion. (A–F) Antisense IL-8 cRNA probe,
(G and H) sense IL-8 cRNA probe (nega-
tive control). Sections were derived from
glioblastoma No. 921 for A and C (bright
field) and B and D (dark field), and glioblas-
toma No. 882 for E and G (bright field) and
F and H (dark field). (A and B were also
used for immunohistochemistry with an
anti-GFAP antibody (A, red filaments; B,
green filaments). (E–H) Pseudopalisading cells
separate a necrotic tumor area with numer-
ous dying cells with pyknotic nuclei (top)
from a viable richly vascularized tumor area
(bottom). Bright areas in H are tumor vessels. 
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IL-8 producer cells in these areas, we performed in situ hy-
bridization with sense and antisense IL-8 cRNA probes on
ex vivo glioblastoma samples. IL-8 messenger RNA (mRNA)
was found in areas surrounding blood vessels, both in those
showing a lumen (Fig. 1, 
 
A
 
 and 
 
B
 
) and in those with glom-
eruloid microvascular proliferation (Fig. 1, 
 
C
 
 and 
 
D
 
) char-
acteristic of glioblastoma (1). This confirms the spatial pattern
of expression observed previously with in situ immunode-
tection (12). Moreover, elevated IL-8 mRNA levels were
observed in cells surrounding necrosis (Fig. 1, 
 
E
 
 and 
 
F
 
).
These cells form a particular structure called pseudopalisade
and are believed to undergo severe stress due to oxygen
deprivation (1). Controls with sense probes on adjacent
sections were negative (Fig. 1, 
 
G
 
 and 
 
H
 
). Staining of these
sections (Fig. 1 
 
A
 
) or adjacent sections (not shown) with an
antibody against GFAP, a glial lineage marker, suggested
 
that the cells expressing IL-8 mRNA were either of glial
origin (astrocytoma cells or reactive astrocytes) or cells in-
filtrating the tumor in areas with intricate patterns of GFAP
expression.
The correlation of IL-8 expression and tumor cell prox-
imity to necrosis prompted us to investigate whether there
was a causal relationship. Therefore, we used an experi-
mental model system in which necrosis forms at the center
of a multicellular tumor spheroid (35, 36). These spheroids
can be easily manipulated in vitro, the appearance of necro-
sis is dependent on spheroid size (150–300 
 
m
 
M diameter),
and measurement of oxygen content in the necrotic region
showed that it was anoxic (35). Another advantage of this
model is that it allows examination of inducing events linked
to necrosis formation without the in vivo complications
linked to the presence of nontumoral cells (microvessel
Figure 2. Detection of IL-8 and VEGF
mRNAs on spheroid sections of glioblastoma
cell line LN-229 by in situ hybridization. (A, B,
and  D–G) Antisense IL-8 cRNA probe, (C
and H) sense IL-8 cRNA probe (negative
control). Green area in H corresponds to ne-
crosis. (I) Antisense VEGF cRNA probe. (J)
VEGF cRNA probe (negative control). (A–
C) 4-d-old spheroid, magnification of 20; (D–
J) 10-d-old spheroids with central necrosis,
magnification of 10. Spheroid in F and G was
incubated for 24 h with TNF (100 U/ml) be-
fore sectioning. 
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cells, microglia, and infiltrating leukocytes). Spheroids were
produced from glioblastoma cells and analyzed for IL-8
mRNA expression by in situ hybridization and Northern
blotting before and after appearance of central necrosis.
Slight constitutive IL-8 mRNA expression was found in
small spheroids without necrosis (diameter of 
 
,
 
150 
 
m
 
m)
under the culture conditions used (Fig. 2, 
 
A
 
 and 
 
B
 
); this
likely reflects serum stimulation of IL-8 expression as previ-
ously shown in monolayer cultures (12). In larger spheroids
(
 
.
 
10 d old) with central necrosis, a ring-like augmentation
of IL-8 mRNA levels was observed (Fig. 2, 
 
D
 
 and 
 
E
 
). This
increase in IL-8 mRNA could be the result of an inductive
event in the stressed cells lining necrosis or an inhibition of
IL-8 mRNA expression in the peripheral cell layer at the
contact of culture medium. To discriminate between these
two possibilities, we incubated the spheroids with TNF-
 
a
 
,
an inflammatory cytokine known to induce IL-8 mRNA pro-
duction. Increase of IL-8 mRNA was now observed both
in the cells lining necrosis and in those at the periphery of
the spheroid (Fig. 2, 
 
F
 
 and 
 
G
 
), showing that the peripheral
cells have not become refractory to an IL-8–inducing stim-
ulus. In situ hybridization of these spheroids with a VEGF
antisense probe (Fig. 2 
 
I
 
) showed that the mRNA increases
observed for both IL-8 and VEGF were similar in both in-
tensity and perinecrotic localization. Control sense cRNA
probes for IL-8 (Fig. 2, 
 
C
 
 and 
 
H
 
) and VEGF (Fig. 2 
 
J
 
) were
negative.
To obtain a quantitative estimate of the increase in IL-8
mRNA production as a result of necrosis development
over time, we performed Northern blotting on 10 
 
m
 
g total
RNA (thus normalizing for differences in cell numbers be-
tween young and old spheroids) extracted from 4-, 7-, and
11-d-old spheroids. Total IL-8 mRNA content of sphe-
roids increased significantly from days 4 to 7 by 2-fold, and
from days 4 to 11 by 7.5-fold (Fig. 3 A). These results
demonstrate that establishment of a necrotic area in glio-
blastoma spheroids is sufficient to generate an increase in
IL-8 mRNA steady state levels in glioblastoma cells, and
that this induction is not dependent on nontumoral accessory
cells.
Induction of IL-8 expression could be the direct result of
physiological conditions of minimal oxygen supply or re-
lated to the presence of factors produced either by dying
cells or liberated by cell lysis during necrosis. To discrimi-
nate between these possibilities, we placed monolayer glio-
blastoma cell cultures under experimental conditions of oxy-
gen deprivation using anaerobic chambers (see Materials
and Methods). These chambers generate complete anoxia
within a time frame of 6–8 h due to oxygen consumption
by a palladium catalyst. Using this system we were able to
demonstrate an increase in IL-8 mRNA levels, as do IL-1
or TNF treatments, in glioblastoma cell lines LN-229 (Fig.
3 B), U87MG, LN-Z308, and T98G (not shown), a panel
representative of the genetic and biological heterogeneity
of glioblastoma (37). IL-8 mRNA peaked between 12 and
24 h after induction (not shown) and resulted in augmenta-
tion of secreted IL-8 in culture medium as measured by
ELISA (Fig. 3 C). Similar results were obtained in cells in-
Figure 3. Measurement of IL-8 mRNA and protein levels in glioblas-
toma cells exposed to anoxia. (A) Time course of IL-8 mRNA levels in
LN-229 glioblastoma cell spheroids by Northern blotting (left) and graph-
ical display of relative mRNA levels (right). 10 mg of total RNA extracted
from 4-, 7-, and 11-d-old spheroids is displayed in each lane. (This nor-
malizes for cell content in spheroids.) (B) Northern blot with RNA ex-
tracted from LN-229 glioblastoma cells, incubated for 24 h in an anoxia-
generating chamber system. N, normoxia; A, anoxia; IL-1, simultaneous
IL-1b treatment at 10 U/ml for 24 h; TNF, TNF-a treatment at 100 U/
ml for 24 h. (C) Measurement of IL-8 by ELISA (picogram per milligram
of total cellular protein) in conditioned media of LN-229 cells after 24 h
of normoxic (white column) or anoxic (black column) treatment. Standard
deviations (vertical bars) of triplicates were calculated. (D) Analysis of cell
number and viability of glioblastoma cell lines upon anoxic treatment.
LN-229 (left) and LN-Z308 (right) glioblastoma cells were stained with
trypan blue and counted before (hatched columns) and after a 24-h treat-
ment under normoxic (white columns) or anoxic (black columns) conditions.
Standard deviations of triplicates (vertical bars) were calculated. The
amount of cells permeable to trypan blue was insignificant and is not pre-
sented in the graph.1206 Upregulation of IL-8 by Oxygen-deprived Cells in Glioblastoma
cubated under a gas mixture composed of 95% N2 and 5%
CO2 (not shown). Cell counting before and after the 24-h
anoxic treatment showed moderate reduction in cell num-
bers (by 20–30%) as compared to untreated cells (Fig. 3 D),
due to a reduced proliferation rate under anoxia. Examina-
tion of morphology and membrane integrity by exclusion
of trypan blue did not show loss of cell viability and there
was no cell detachment from the monolayer. This demon-
strates that IL-8 induction is not due to cell products re-
leased from lysing cells, but rather a biological response to
anoxic stress. Furthermore, the induction was obtained ir-
respective of the endogenous wild-type or mutant p53
gene status of the cell lines analyzed (37), suggesting that it
was not linked to hypoxia-induced p53 (38). This is partic-
ularly relevant since consensus binding sites for the p53
transcription factor (39) are present in the IL-8 gene. To
directly evaluate whether WTp53 could increase IL-8
mRNA levels, we used a clone of glioblastoma cell line
T98G in which WTp53 expression can be conditionally
induced by dexamethasone (40). No difference in IL-8
mRNA content was found in p53-induced and nonin-
duced cells by Northern blotting (not shown).
The biological relevance of IL-8 expression in glioblas-
toma depends on the presence of cells with receptors capa-
ble of binding IL-8. Therefore, we evaluated whether IL-8
might have autocrine and/or paracrine functions in vivo.
First, we examined CXCR1, CXCR2, and DARC mRNA
expression by RT/PCR. CXCR1 mRNA was found in 5
of 5 grade II, 1 of 7 grade III, and 8 of 12 grade IV astrocy-
toma. CXCR2 mRNA was found in 5 of 5 grade II, 6 of 7
Figure 4. Detection of IL-8–binding
receptors in glioblastoma by immunohis-
tochemistry. DARC (A) and factor VIII
(B) expression on microvascular cells of
glioblastoma No. 1069. DARC (C) and
preimmune serum (D) staining on nontu-
moral brain No. T265CN. CXCR1 (E)
and CD3 (F) staining on glioblastoma No.
906. CXCR2 staining on sections with
vessels (G) or in a perinecrotic region (H)
of glioblastoma No. 842. Examples of posi-
tive cells are shown by arrows.1207 Desbaillets et al.
grade III, and 11 of 12 grade IV. DARC mRNA was
found in 3 of 5 grade II, 5 of 7 grade III, and 10 of 12 grade
IV (results not shown). This suggested that IL-8 may serve
a biological function during the progression of human as-
trocytoma in vivo, either on tumor cells or on accessory cells.
Next, we examined which cell types expressed IL-8–bind-
ing receptors in vivo by immunohistochemistry (represen-
tative stainings are shown in Fig. 4). Very interestingly,
DARC was specifically expressed by microvascular cells in
5 of 6 grade II, 5 of 6 grade III, and 14 of 19 grade IV as-
trocytomas (Fig. 4 A) with a staining pattern similar to the
one obtained for factor VIII, a microvascular marker (Fig. 4
B). DARC expression was also present on 5 of 5 nontu-
moral brains (Fig. 4 C). Control stainings with preimmune
serum was negative on all samples (Fig. 4 D). In contrast,
for both CXCR1 and CXCR2, isolated positive cells were
found surrounding blood vessels. For CXCR1, 2 of 9
grade II, 1 of 3 grade III, and 5 of 18 grade IV were posi-
tive (Fig. 4 E), and for CXCR2, 1 of 9 grade II, 0 of 3
grade III, and 5 of 18 grade IV (Fig. 4 G). Staining of adja-
cent sections for CD3, a specific marker of T lymphocytes
(Fig. 4 F), and CD15, a macrophage marker (not shown),
showed infiltrates in these areas, suggesting expression by a
subset of T lymphocytes and/or macrophages. Unfrequently,
numerous CXCR2 positive cells were found close to ne-
crosis (Fig. 4 H).
To confirm the CXCR1- and CXCR2-expressing cells
detected by immunohistochemistry, we performed in situ
hybridization on three glioblastomas. Specific signals for
both CXCR1 (Fig. 5, A–D) and CXCR2 (Fig. 5, G–J)
Figure 5. Detection of IL-8–binding re-
ceptors CXCR1 and CXCR2 mRNAs in
glioblastoma sections by in situ hybridization.
(A–D) Antisense CXCR1 cRNA probe, (E
and F) negative control sense CXCR1 cRNA
probe, (G–J) antisense CXCR2 cRNA
probe, (K) negative control sense CXCR2
cRNA probe. Sections were derived from
glioblastoma No. 921 for A and G (bright
field) and B and H (dark field), glioblastoma
No. 892 for C and E (bright field) and D and
F (dark field), and glioblastoma No. 882 for I
(bright field), J and K (dark field). Immuno-
histochemistry with an anti-GFAP antibody
was used for sections A and B (A, red filaments,
and B, green-brown filaments) and with an anti-
smooth muscle actin antibody for E and F.1208 Upregulation of IL-8 by Oxygen-deprived Cells in Glioblastoma
mRNAs were found on small isolated cells surrounding
vessels, with a morphology compatible with lymphoid or
myeloid infiltrates. Double staining with an anti-GFAP an-
tibody failed to associate these cells with GFAP filaments
(Fig. 5 A). Control with sense probes for CXCR1 (Fig. 5,
E and F) and CXCR2 (Fig. 5 K) were negative. These data
are consistent with expression by infiltrating leukocytes and
confirm immunostaining results.
Discussion
Morphological examination of the malignant progression
of astrocytoma shows that the transition to the most malig-
nant form (glioblastoma) is defined by the appearance of
necrosis (1). It is intriguing that a decrease in physiological
oxygen pressure, ultimately lethal to tumor cells, coincides
with maximal tumor aggressiveness. This raises the ques-
tion as to whether the hypoxic/ischemic conditions in-
creasing at this stage are a consequence or a cause of in-
creased malignancy. The appearance of necrosis is also
closely associated with the ultimate changes in the angio-
genic phenotype of glioblastoma. The mRNA for VEGF,
an endothelial-specific angiogenic mitogen, is upregulated
by hypoxia in glioma cells in vitro and is overexpressed in
cells lining necrotic areas in vivo (41, 42, 36). VEGF recep-
tor type 2 mRNA is upregulated on endothelial cells in
glioblastoma, and studies with animal models of glioma
have shown that vessel development and tumor growth
were partially inhibited by anti-VEGF antibodies (43),
overexpression of a dominant negative VEGF receptor
mutant (44), or antisense VEGF gene constructs (45, 46).
These results demonstrate that hypoxic regulation of VEGF
is of biological consequence for the angiogenic phenotype
associated with the transition to the most malignant form of
astrocytoma. The factors inducing neovascularization in the
early phases of astrocytoma development are less well char-
acterized (3). The presence of residual tumor upon anti-
VEGF treatment further suggests that more than one factor
ensures angiogenic supply to support astrocytoma growth.
Finally, because astrocytoma cells also secrete angiogenic
inhibitors (47) and cytokines such as IL-6 (30) or leukemia
inhibitory factor (LIF) (our unpublished results) with anti-
angiogenic properties (48), the final angiogenic response
will be determined by the balance between positive and
negative regulators (2).
Here we demonstrate that IL-8, another soluble biologi-
cal mediator with angiogenic and chemotactic properties, is
upregulated in cells surrounding necrosis in glioblastoma
and that IL-8–binding receptors are concomitantly ex-
pressed in vivo. IL-8 is the best studied member of the
chemokines, a class of cytokines extensively analyzed for
their ability to attract and activate leukocytes during in-
flammation (see review in reference 13). It has previously
been demonstrated that upon induction by inflammatory
cytokines IL-1 and TNF astrocytoma cells release a variety
of cytokines in vitro, including biologically active IL-8 (see
review in reference 49). In vivo, it was unclear whether cy-
tokine expression resulted from indirect induction by tu-
mor-related inflammatory responses or was directly linked
to tumor growth and progression.
We now confirm the presence of IL-8 expression in as-
trocytoma and show that it is likely to occur by two dis-
tinct mechanisms during the progression of astrocytoma.
Initial upregulation may be mediated by stimulatory signals
such as proinflammatory cytokines (e.g., IL-1 or TNF),
which induce IL-8 in astrocytoma cells in vitro and can be
present in glioma, in glioma-associated cyst fluid, and in
cerebrospinal fluid derived from glioma patients (see re-
view in reference 49). Later in disease progression, strong
IL-8 upregulation is observed in cells surrounding necrotic
areas in glioblastoma, suggesting further induction by hy-
poxia/ischemia. This hypothesis was sustained by increased
IL-8 mRNA and protein expression upon in vitro expo-
sure of glioblastoma cells to anoxia as monolayer cultures
or in the central necrosis of three-dimensional spheroids.
These experiments further showed that this increase was
not dependent on nontumoral accessory cells or on stimu-
lation by factors released by dying tumor cells. Thus, IL-8
increase in late stage astrocytoma is most likely to be due to
physiological changes in oxygen pressure occurring during
tumor growth, although we cannot exclude participation
of accessory cells such as macrophages, microglia, or reac-
tive astrocytes in vivo.
The influence of altered oxygen concentrations on IL-8
expression has previously been demonstrated in the context
of ischemia reperfusion. Human umbilical vein endothelial
cells were shown to upregulate IL-8 during hypoxia (50) as
were monocytes during reoxygenation (51). Here, we
show that similar IL-8–inducing events may occur in the
pathologic process of cancer. Tumor cells and/or tumor-infil-
trating macrophages or microglia upregulate IL-8 expres-
sion which may play important functions in tumor angio-
genesis and tumor immune interactions through paracrine
stimulation of cognate receptors. Upregulation of IL-8 in tu-
mor endothelial cells was not observed in astrocytoma, and
may reflect differences in endothelial subtypes, the abnor-
mal structure of the tumor endothelium, as well as tissue
environment (12) or rapid internalization after binding to
DARC (52).
IL-8 induction is relevant to the biology of the tumor
since we detected the expression of IL-8 receptor mRNA
and protein. Tumor cells did not express IL-8 receptors in
vivo demonstrating that IL-8 does not participate in an au-
tocrine growth regulatory loop mediated by any of these
three receptors. However, IL-8 receptor expression pattern
suggests two functions for IL-8 in astrocytoma.
First, the constitutive expression of the DARC receptor
on normal brain and tumor microvasculature supports an
angiogenic function for IL-8 in astrocytoma. This is sus-
tained by a recent report in which the angiogenic factors
present in the supernatant of glioma cell lines were evalu-
ated in an in vitro angiogenic assay using human microvas-
cular endothelial cells. The authors showed with antibody
neutralization assays that the angiogenic response was pri-
marily due to IL-8 or the combination of VEGF and
bFGF, depending on the cell line analyzed (53). Clearly,1209 Desbaillets et al.
further in vivo studies will have to establish whether IL-8
and other angiogenic chemokines are essential contributors
to the angiogenic response seen in astrocytoma, whether
this response is mediated by DARC, and whether they act
in synergy with VEGF or represent alternative angiogenic
routes. This is, to our knowledge, the first report of DARC
expression on tumor vasculature. The presence of DARC
on normal endothelial cells lining postcapillary venules in
kidney, spleen, lung, and brain (32, 29, 54), cells poten-
tially constitutively responsive to IL-8, may implicate
DARC in early tumor angiogenesis. It is noteworthy that
this vascular staining is not the result of vessel cell or extra-
cellular matrix binding of DARC released from erythro-
cytes, since this staining was maintained in individuals lack-
ing erythroid DARC gene expression, due to a mutation
disrupting a binding site for the GATA1 erythroid tran-
scription factor in the DARC gene promoter (52, 55). Fur-
thermore, these results designate DARC as a prime candi-
date endothelial receptor to explain endothelial cell binding
and direct angiogenic responses mediated by IL-8 (20–22,
56, 57). This should stimulate the deciphering of the
downstream effector mechanisms, likely the demonstration
that DARC elicits an intracellular signal upon ligand bind-
ing in microvascular cells. Lastly, due to the promiscuous
nature of the DARC receptor, a variety of C-C and C-X-C
chemokines expressed by astrocytoma (see review in refer-
ence 49) may bind tumor microvascular cells. The conver-
gence of a large panel of potentially angiogenic cytokines
(58) in the use of a single microvascular receptor, might
designate DARC as a target of choice for therapeutic inter-
ference at what might become the “Achilles’ heel” of
chemokine redundancy.
Second, the expression of CXCR1 and CXCR2 on a
subset of infiltrating lymphoid and/or myeloid cells is com-
patible with a role for IL-8 as chemotactic and activating
agent for leukocytes in astrocytoma, as suggested in other
systems (14, 15, 17–19). It will be of interest to further
characterize this leukocyte subset and to study its function
in the tumor immune system relationship and as an indirect
elicitor of angiogenesis through cytokine release (59, 60). It
should also be mentioned that if IL-8 chemoattracts T lym-
phocytes, other astrocytoma-expressed leukocyte chemoat-
tractants, such as MCP-1 (11, 61) are certainly involved,
since CXCR1 and CXCR2 expression was found on only
a fraction of leukocytic infiltrates. The reasons for the rare
occurence of neutrophils in astrocytoma/glioblastoma de-
spite functional IL-8 inducing signals are unknown and
were previously discussed (12). Additional hypotheses in-
clude inappropriate expression of homing signals, such as
specific selectins (62), potential killing of Fas-expressing
neutrophils (63) by Fas ligand expressed by tumor cells (64,
65), disappearance/physiological downregulation by recep-
tor desensitization (66), excessive release of IL-8 in circulation
leading to saturation (67), or inactivation of chemoattrac-
tant ability due to cleavage by aminopeptidase N (CD13) (68).
In conclusion, our results support a model where early in
astrocytoma development tumor-related inflammatory re-
sponses trigger IL-8 and VEGF release. This would elicit
direct and/or indirect angiogenic responses through bind-
ing of IL-8 to the DARC receptor expressed constitutively
on brain microvascular cells and CXCR1 and CXCR2 re-
ceptors on leukocytes. Chemoattracted leukocytes infiltrate
the tumor and their activation induces release of cell prod-
ucts/cytokines with angiogenic potential. VEGF release in-
duced by inflammatory signals might exert its first action
when VEGFR1 expression appears in low grade astrocy-
toma (3). Later in astrocytoma progression and in de novo
glioblastoma, induction of IL-8 and VEGF production by
reduced oxygen pressure and appearance of expression of
VEGFR2 (3) would further contribute, besides other fac-
tors, to the florid microvascular proliferation characteristic
of glioblastoma. The understanding of the molecular
mechanisms at the origin of tumor neovascularization, es-
pecially at early disease stages, should permit the develop-
ment of new therapeutic modalities targeted at specific an-
giogenic effectors.
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